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See related article on page 698. There is no operation as complex, yet as fundamentally unchangedover time, as conventional coronary artery bypass grafting (CABG).This remarkable achievement is credited to the operation’s adapt-ability to a wide variety of clinical settings; its reproducibility anddurability while performed by a vast cadre of surgeons all across theworld; and its proven track record for safety and effectiveness. A
momentous effort, however, is evolving to redefine CABG. This paradigm shift has
received a groundswell of support as advances in minimally invasive surgery in
other areas, such as arthroscopy, laparoscopic cholecystectomy, and thoracoscopy,
combined with an increasing focus on cost containment, have forever changed the
milieu of the cardiac surgeon.
The clinical effectiveness of the left internal thoracic artery–to–left anterior
descending coronary artery anastomosis combined with the considerable morbidity
associated with conventional CABG provided the impetus for exploring alternative
approaches to surgical revascularization. These approaches have all fallen under the
general rubric of minimally invasive CABG. The clinical goals of minimally
invasive CABG are interrelated and include (in order of importance): (1) achieving
graft patency rates equal or superior to those of conventional CABG (avoid repeated
revascularization); (2) decreasing incisional pain and discomfort (reduce invasive-
ness); (3) facilitating a more rapid return to normal activity levels (reduce invasive-
ness); (4) reducing the length of hospital stay (decrease complications); and (5)
decreasing cost. Currently, the most widely practiced minimally invasive approach
involves surgical revascularization on the beating heart through a median sternot-
omy incision, or off-pump coronary artery bypass grafting (OPCAB). Best industry
estimates are that OPCAB, and other beating heart techniques, constituted approx-
imately 24.7% of the 350,000 isolated CABG operations performed in 2001 (per-
sonal communication from Medtronic, Inc, Minneapolis, Minn, December 2001).
Despite tremendous enthusiasm on the part of patients, industry, and the media,
however, widespread adoption will not occur until OPCAB is validated through the
explicit and conscientious assessment of current best evidence.
Accordingly, what is the current best evidence available relating to OPCAB? A
logical and comprehensive approach to evaluating clinically relevant research
incorporates many different types of evidence (including randomized clinical trials
[RCTs], nonrandomized clinical trials [non-RCTs], and experimental data) and
analyzes the information’s content for consistency, coherence, and clarity. A useful
metric for the assessment of clinical research is shown in Table 1.1
In the hierarchy of clinical evidence, the RCT is generally considered the best
approach to ascertain the value of a particular therapy. RCTs compare outcomes in
a group of patients to which a test treatment (eg, OPCAB) has been applied with
those observed in a comparable group of patients receiving a control treatment (eg,
conventional CABG). Ideally, patients in the treatment and control arms are iden-
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tical in every way such that any difference in outcomes
between the two groups can be attributed exclusively to
their respective treatments. Advantages of the RCT include
adherence to the experimental method and the absence of
selection bias. Disadvantages, however, include the consid-
erable time, resources, and expense required to complete
trials sufficiently large to demonstrate important differences
in outcome, particularly when the observed incidence of
differences in outcome is low (eg, operative mortality after
surgical revascularization). Furthermore, the generalizabil-
ity of the study’s results beyond specific inclusion and
exclusion criteria can be legitimately questioned. Therefore,
much data regarding clinical outcomes is gained by obser-
vational studies including the propensity score computer-
matched study by Sabik and associates2 in this issue of the
Journal.
In OPCAB, numerous studies have been conducted to
address a variety of important clinical outcomes, including
(1) early graft patency, (2) blood loss and blood transfusion
requirements, (3) acute renal failure, (4) myocardial protec-
tion, (5) adverse neurologic events, (6) length of hospital
stay, (7) morbidity, and (8) mortality.
Early Graft Patency
The major obstacle to achieving an effective coronary anas-
tomosis in OPCAB is the translational motion of the beating
heart. In OPCAB, translational motion is generally con-
strained by means of a mechanical stabilizer. Although
adequate for immobilizing the left anterior descending cor-
onary artery in most cases, the device’s stabilizing effi-
ciency is reduced in the lateral circumflex and inferior
distributions and entails a significant learning curve. The
few large studies of graft patency after beating heart CABG
are mostly limited to the left internal thoracic artery–to–left
anterior descending coronary artery anastomosis and pro-
vide only short-term follow-up (Table 2).3-6 Of 200 patients
reported by Puskas and coworkers,5 167 (83.5%) underwent
a baseline angiographic evaluation before hospital dis-
charge. Wide graft patency with unimpaired runoff
(FitzGibbon grade A) to the target vessels was as follows:
left anterior descending coronary artery, 145 of 160 (91%);
obtuse marginal branch, 68 of 74 (92%); posterior descend-
ing artery, 65 of 68 (96%); and right coronary artery, 26 of
26 (100%).
Conclusion: In OPCAB, the left internal thoracic ar-
tery–to–left anterior descending coronary artery anastomo-
sis can be accomplished with acceptable early graft patency
in selected patients (grade B). Extrapolating this finding to
anastomoses in the lateral and inferior distributions is pre-
mature at this time.
Blood Loss and Blood Transfusion Requirements
By exposing blood to the foreign materials present in the
bypass circuit, cardiopulmonary bypass incites a systemic
inflammatory response syndrome mediated by complement
activation and cytokine release.7 This in turn promotes
neutrophil activation, enhanced capillary permeability, in-
terstitial edema, decreased systemic vascular resistance, and
maldistribution of end-organ blood flow. This syndrome can
manifest clinically as perioperative bleeding and acute renal
failure. Three prospective RCTs have examined the issue of
perioperative bleeding and the consequent transfusion re-
quirement. Ascione and colleagues8 prospectively random-
ized 200 patients to OPCAB and conventional CABG. They
observed that fewer OPCAB patients required blood trans-
fusion (23% vs 52%, P  .01). van Dijk and associates9
prospectively randomized 281 patients and similarly re-
ported fewer blood transfusions in the OPCAB group (3%
TABLE 1. Grading of recommendations and levels of evi-
dence*
*Adapted from Yusuf S, Cairns JA, Camm AJ, Fallen EL, Gersh BJ, editors.
Evidence Based Cardiology. London: BMJ Books; 1998.
TABLE 2. Angiographic graft patency rates after OPCAB
First author
No. of
patients
Angiograms No. of
grafts
Graft patency
rate (%)No. %
Calafiore 122 67 54.9 185 98.5*
Mack 103 100 97 100 91.0*
Bull 40 NA 108 97.0†
Puskas 200 167 83.5 421 93.3*
NA, Not available.
*FitzGibbon grade A (J Am Coll Cardiol. 1996;28:616-26).
†Definition of patency not given.
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Table available in print only
vs 13%, P  .01). Several non-RCTs have specifically
addressed perioperative bleeding, and all have uniformly
reported significantly less shed mediastinal blood loss after
OPCAB: 148  140 mL (n  60) versus 386  300 mL
(n  55), P  .0210; 771  66 mL (n  66) versus 1084 
82 mL (n 60), P .0511; 403 407 mL (n 472) versus
613  453 mL (n  290), P  .00112; and 694  692 mL
(n  350) versus 909  617 mL (n  3171), P  .001.13
Conclusion: OPCAB favorably reduces blood transfu-
sion requirements (grade A) and may reduce perioperative
blood loss (grade B) compared with conventional CABG.
Acute Renal Failure
In a prospective study by Ascione and associates,14 50
patients were randomized to OPCAB and conventional
CABG. Renal glomerular filtration rate was measured by
using creatinine clearance and computing the urinary mi-
croalbumin/creatinine ratio, and renal tubular function was
assessed by measuring urinary N-acetyl glucosaminidase.
Both laboratory determinants of renal function were favor-
ably improved in the OPCAB group; however, the fre-
quency of clinically important renal failure was not signif-
icantly different. Failure to detect a significant difference in
this clinical end point can be attributed to its relatively small
size, as well as the low observed incidence of acute renal
failure in this population. In three non-RCTs, acute renal
failure, defined as a greater than 50% increase in baseline
creatinine or a need for dialysis, was significantly improved
with OPCAB compared with conventional CABG: 3.85%
(n  11,717) versus 4.26% (n  106,423), P  .03615;
0.87% (n 346) versus 2.75% (n 2,545), P .03616; and
0% (n  406) versus 1.5% (n  406), P  .030.2
Conclusion: OPCAB may favorably reduce the inci-
dence of acute renal failure (grade B) after surgical revas-
cularization compared with conventional CABG.
Myocardial Protection
Because it uses regional rather than global ischemia to
provide a bloodless operative field, OPCAB has been pos-
tulated to cause less myocardial damage. Two prospective
RCTs have demonstrated improved myocardial protection
with OPCAB compared with conventional CABG based on
lower peak creatine kinase MB fractions: 6.3 g/L (n 11)
versus 15.1 g/L (n  11), P  .008,17 and 21  14 g/L
(n  25) versus 30  6 g/L (n  25), P  .0418; in a third
RCT, improved myocardial protection was demonstrated by
the creatine kinase MB fraction area-under-the-curve (164.0
vs 277.0, P  .01).9
Conclusion: OPCAB may provide superior myocardial
protection (grade A) and less myocardial necrosis compared
with conventional CABG using cardioplegic arrest.
Adverse Neurologic Events
In a recent report by the Perioperative Ischemia Research
Group, 2108 patients undergoing elective conventional
CABG were prospectively evaluated for adverse neurologic
events.19 Stroke was observed in 3.1% of patients and
cognitive dysfunction or seizures were reported in 3.0%.
Significantly, adverse neurologic events were associated
with a 5- to 10-fold increase in mortality and doubling of the
length of hospitalization. Also, between 30% and 47% of
these patients were transferred to intermediate- or long-term
care facilities compared with 8% of patients without adverse
cerebral outcomes. The most powerful predictor of stroke
was the presence of moderate or severe proximal aortic
atherosclerosis detected by palpation. This finding provides
compelling evidence that most postoperative strokes are
related to cerebral microemboli arising from surgical ma-
nipulation of the ascending aorta; for example, during aortic
cannulation and initiation of cardiopulmonary bypass, aortic
crossclamping, and partial occlusion clamping. Thus, ad-
verse neurologic events arising from the surgical manipu-
lation of the aorta can significantly increase mortality,
length of hospitalization, and cost of CABG.
In the only prospective RCT large enough (n  281) to
potentially detect a clinically important difference in post-
operative stroke, van Dijk and colleagues9 did not detect a
significant difference in the incidence of stroke after OP-
CAB compared with conventional CABG (0.7% vs 1.4%).
Two large non-RCTs also failed to demonstrate significant
improvement in stroke after OPCAB: 1.3% (n  1741)
versus 1.8% (n  6126)20 and 0.7% (n  406) versus 1.2%
(n  406).2 In contrast, two other large non-RCTs reported
substantial improvement in stroke rates after OPCAB com-
pared with conventional CABG: 0.8% (n  472) versus
6.9% (n  290), P  .05,12 and 1.25% (n  11,717) versus
1.99% (n  106,423), P  .001.15 Of importance, when
attachment of saphenous vein grafts to the aorta was re-
quired, all of the referenced studies used partial aortic
clamping to facilitate the proximal anastomosis. Hence, the
benefit of completely avoiding aortic clamping by means of
sutureless aorta–saphenous graft connectors remains spec-
ulative.21
Conclusion: On the basis of conflicting non-RCTs, the
lack of concordant RCT data, and the failure to use newer
technology that potentially can reduce cerebral microem-
boli, the benefit of OPCAB on adverse neurologic events
remains uncertain.
Length of Hospital Stay and Overall Morbidity
The length of hospital stay after coronary artery bypass is a
function of numerous factors relating to patient demograph-
ics (eg, age and sex); comorbid conditions (eg, diabetes and
chronic obstructive pulmonary disease); severity of coro-
nary heart disease (eg, New York Heart Association func-
tional class, number of involved coronary arteries, and
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degree and location of arterial stenoses); and postoperative
morbidity (eg, atrial arrhythmia, prolonged inotropic sup-
port, prolonged mechanical ventilatory support, and bleed-
ing).5 In the prospective study by van Dijk and colleagues,9
281 patients were randomized to OPCAB or conventional
CABG. OPCAB was associated with a significantly reduced
length of hospital stay (6 days vs 7 days, P  .01). Several
non-RCTs using contemporaneous control groups have also
demonstrated a substantial decrease in hospital stay between
OPCAB and conventional CABG: 3.9 2.6 days (n 200)
versus 5.7  5.3 days (n  1000), P  .0015; 4.0  1.8
(n  472) versus 4.7  1.8 (n  290), P  .00113; 4.1 
1.6 (n  185) versus 5.4  2.4 (n  67), P  .0013; and
6.1  3.6 (n  350) versus 7.1  6.4 (n  3171), P 
.001.13
Two large non-RCTs examined the overall morbidity
after OPCAB compared with conventional CABG.15,22 Both
studies demonstrated clear superiority of OPCAB in reduc-
ing overall risk-adjusted morbidity (Table 3).
Conclusion: OPCAB is associated with shortened
length of hospital stay (grade A) and may favorably reduce
overall morbidity (grade B) compared with conventional
CABG.
Mortality
Similar to postoperative morbidity, mortality after coronary
bypass grafting is dependent on numerous factors, including
patient demographics, comorbid conditions, coronary heart
disease severity, and postoperative morbidity. Moreover, a
few studies have implicated the use of cardiopulmonary
bypass with hospital mortality.5,23 In the prospective RCT
by van Dijk and coworkers,9 the 30-day mortality between
OPCAB and conventional CABG arms was not significantly
different: 0% (n  142) versus 0% (n  139). Among
several large non-RCTs of primary coronary artery bypass,
hospital mortality was improved with OPCAB in two stud-
ies: 1.4% (n 919) versus 3.0% (n 924), P .016,24 and
2.6% (n  472) versus 8.7% (n  290), P  .001.12
However, mortality was not significantly improved in two
others.2,13 Risk-adjusted mortality was examined in four
large non-RCTs.15,20,22,25 Three studies suggested that OP-
CAB was safe and not associated with increased mortality,
whereas one study demonstrated significant improvement in
risk-adjusted mortality (Table 4).
Of note, two small non-RCTs focused primarily on the
differences in operative mortality among high-risk sub-
groups of patients—reoperations26 and predicted operative
mortality greater than 5%.13 In both studies, OPCAB was
associated with significantly improved observed mortality
compared with conventional CABG: 1.0% (n  41) versus
10.0% (n  91), P  .03, and 7.7% (n  39) versus 28.5%
(n  123), P  .008.
Conclusion: The operative mortality associated with
OPCAB is no worse and may be significantly better than
that accompanying conventional CABG, particularly in cer-
tain high-risk subsets (grade B).
Six years ago, Lytle27 surveyed the “state of the science”
of minimally invasive cardiac surgery. He correctly forecast
that “the concepts of less invasive surgery will strongly
influence adult cardiac surgery over the next decade” and
warned about safety and the extent of compromise in the
operative result that is acceptable with the following cau-
tion:
The door’s open but the ride it ain’t free.
—B. Springsteen
We are now 6 years down this road and indeed the
practice adult cardiac surgery has significantly changed. As
one views success of catheter-based revascularization and
the advent of drug-eluting stents promising to diminish
restenosis on the horizon, one must constantly re-evaluate
the role surgical revascularization will play (now less than
30% of all coronary revascularizations). However, the con-
tinued success of coronary artery bypass surgery is main-
tained by minimizing procedural trauma without compro-
mising long-term outcomes in a user-friendly manner that is
widely applicable and teachable.
To further quote Lytle’s bard from Thunder Road:
We have one last chance to make it real.
—B. Springsteen
TABLE 3. Comparison of observed and expected overall
morbidity
First
author
OPCAB CABG
P value*
Observed
(%)
Expected
(%)
Observed
(%)
Expected
(%)
Plomondon 8.80 13.20 14.00 11.90 .05
Cleveland 9.24 11.66 12.15 11.88 .0001
OPCAB, Off-pump coronary artery bypass; CABG, coronary artery bypass
grafting.
*Compares risk-adjusted overall morbidity.
TABLE 4. Comparison of observed and expected mortality
First
author
OPCAB CABG
P value*
Observed
(%)
Expected
(%)
Observed
(%)
Expected
(%)
Hernandez 2.54 2.67 2.57 2.67 .567
Plomondon 2.70 4.40 4.00 3.90 .101
Kshettry 0.74 2.70 2.13 2.30 .484
Cleveland 2.32 2.88 2.94 2.87 .001
NS, Not significant.
*Compares risk-adjusted overall morbidity.
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